Analysts See $0.74 EPS for Abbott Laboratories (ABT)

September 15, 2018 - By Margaret Guttierez

Abbott Laboratories (NYSE:ABT) LogoInvestors sentiment increased to 0.86 in Q2 2018. Its up 0.03, from 0.83 in 2018Q1. It increased, as 41 investors sold Abbott Laboratories shares while 583 reduced holdings. 117 funds opened positions while 420 raised stakes. 1.23 billion shares or 0.63% more from 1.22 billion shares in 2018Q1 were reported.
Legal General Grp Inc Plc owns 7.55M shares or 0.36% of their US portfolio. Legacy Private Trust reported 4,141 shares stake. Dsm Prtn Limited Com invested 2.7% of its portfolio in Abbott Laboratories (NYSE:ABT). Citigroup owns 884,910 shares. Security National Company holds 28,310 shares. Finemark Comml Bank Tru invested in 102,306 shares. Cranbrook Wealth Limited Liability, a Michigan-based fund reported 580 shares. Curbstone Financial Mgmt Corp accumulated 0.68% or 40,162 shares. Gateway Inv Advisers Lc reported 1.02 million shares or 0.55% of all its holdings. Carnegie Cap Asset Ltd Limited Liability Company reported 65,617 shares or 0.32% of all its holdings. South Texas Money Mngmt Limited owns 10,769 shares. Paw, a Connecticut-based fund reported 10,000 shares. Mitchell Mcleod Pugh Williams holds 6,969 shares or 0.3% of its portfolio. 3.34M are owned by Adage Grp Inc Limited Liability Corp. Mcrae Capital stated it has 8,954 shares.

Since April 23, 2018, it had 0 insider purchases, and 9 selling transactions for $10.53 million activity. LANE ANDREW H also sold $610,513 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, August 29. CAPEK JOHN M sold 64,900 shares worth $4.22M. 3,000 Abbott Laboratories (NYSE:ABT) shares with value of $183,592 were sold by Salvadori Daniel Gesua Sive. Contreras Jaime had sold 849 shares worth $50,397 on Monday, April 23. Blaser Brian J also sold $965,789 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, July 24. PEDERSON MICHAEL J sold $66,601 worth of stock.

Analysts expect Abbott Laboratories (NYSE:ABT) to report $0.74 EPS on October, 17.They anticipate $0.08 EPS change or 12.12 % from last quarter’s $0.66 EPS. ABT’s profit would be $1.30 billion giving it 23.11 P/E if the $0.74 EPS is correct. After having $0.73 EPS previously, Abbott Laboratories’s analysts see 1.37 % EPS growth. The stock decreased 0.12% or $0.08 during the last trading session, reaching $68.42. About 4.22M shares traded. Abbott Laboratories (NYSE:ABT) has risen 28.17% since September 16, 2017 and is uptrending. It has outperformed by 12.55% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 4 analysts covering Abbott Labs (NYSE:ABT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Abbott Labs had 4 analyst reports since April 18, 2018 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, July 19. Jefferies maintained the stock with “Buy” rating in Wednesday, April 18 report. On Tuesday, April 24 the stock rating was maintained by Citigroup with “Neutral”.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $120.03 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 131.07 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

More recent Abbott Laboratories (NYSE:ABT) news were published by: Forbes.com which released: “What Will Drive Abbott Labs’ Near-Term Growth?” on August 24, 2018. Also Seekingalpha.com published the news titled: “FDA OKs Biotronik device for coronary artery perforations” on September 14, 2018. Seekingalpha.com‘s news article titled: “India bans 328 combo drugs, Abbott appeals” with publication date: September 13, 2018 was also an interesting one.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.